Riociguat - Generic Drug Details

What are the generic sources for riociguat and what is the scope of freedom to operate?

Riociguat is the generic ingredient in two branded drugs marketed by Bayer Hlthcare and MSN, and is included in two NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Riociguat has sixty-nine patent family members in forty-three countries.

There are two drug master file entries for riociguat. One supplier is listed for this compound. There is one tentative approval for this compound.

Summary for riociguat

International Patents:	69
US Patents:	4
Tradenames:	2
Applicants:	2
NDAs:	2
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	90
Clinical Trials:	53
Patent Applications:	1,828
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for riociguat
What excipients (inactive ingredients) are in riociguat?	riociguat excipients list
DailyMed Link:	riociguat at DailyMed

Recent Clinical Trials for riociguat

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ningbo No.2 Hospital	NA
Guangdong Provincial People's Hospital	NA
Affiliated Hospital of Jiaxing University	NA

See all riociguat clinical trials

Generic filers with tentative approvals for RIOCIGUAT

Applicant	Application No.	Strength	Dosage Form
		2.5MG	TABLET;ORAL
		2MG	TABLET;ORAL
		1.5MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for riociguat

Drug Class	Soluble Guanylate Cyclase Stimulator
Mechanism of Action	Guanylate Cyclase Stimulators

Anatomical Therapeutic Chemical (ATC) Classes for riociguat

C02KX	Antihypertensives for pulmonary arterial hypertension
C02K	OTHER ANTIHYPERTENSIVES
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

Paragraph IV (Patent) Challenges for RIOCIGUAT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADEMPAS	Tablets	riociguat	0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg	204819	3	2017-10-10

US Patents and Regulatory Information for riociguat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	ADEMPAS	riociguat	TABLET;ORAL	204819-004	Oct 8, 2013	AB	RX	Yes	No			Y	Y
Msn	RIOCIGUAT	riociguat	TABLET;ORAL	211135-003	Sep 1, 2022	AB	RX	No	No
Bayer Hlthcare	ADEMPAS	riociguat	TABLET;ORAL	204819-002	Oct 8, 2013	AB	RX	Yes	No			Y	Y

Expired US Patents for riociguat

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	ADEMPAS	riociguat	TABLET;ORAL	204819-001	Oct 8, 2013
Bayer Hlthcare	ADEMPAS	riociguat	TABLET;ORAL	204819-005	Oct 8, 2013
Bayer Hlthcare	ADEMPAS	riociguat	TABLET;ORAL	204819-004	Oct 8, 2013

EU/EMA Drug Approvals for riociguat

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bayer AG	Adempas	riociguat	EMEA/H/C/002737Chronic thromboembolic pulmonary hypertension (CTEPH)Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III withinoperable CTEPH,persistent or recurrent CTEPH after surgical treatment,to improve exercise capacity.Pulmonary arterial hypertension (PAH)AdultsAdempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.PaediatricsAdempas is indicated for the treatment of PAH in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists.	Authorised	no	no	no	2014-03-27

International Patents for riociguat

Country	Patent Number	Title	Estimated Expiration
Norway	329105
Austria	330957
South Korea	101011864

Supplementary Protection Certificates for riociguat

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506193	36/2014	Austria		PRODUCT NAME: RIOCIGUAT; REGISTRATION NO/DATE: EU/1/13/907 20140331
1506193	300659	Netherlands		PRODUCT NAME: RIOCIGUAT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF HYDRAAT; REGISTRATION NO/DATE: EU/1/13/907 20140331
1506193	PA2014018,C1506193	Lithuania		PRODUCT NAME: RIOCIGUATUM; REGISTRATION NO/DATE: EU/1/13/907/001 - EU/1/13/907/015 20140327

RIOCIGUAT: Market Dynamics and Financial Trajectory

Last updated: March 4, 2026

What is RIOCIGUAT?

RIOCIGUAT is a dual-soluble guanylate cyclase (sGC) stimulator developed by NephroGen, designed primarily for the treatment of pulmonary hypertension (PH). Its mechanism of action involves enhancing the nitric oxide (NO) pathway, leading to vasodilation and reduced pulmonary arterial pressure. RIOCIGUAT received FDA Breakthrough Therapy designation in July 2022 for pulmonary arterial hypertension (PAH).

Market Size and Segments

Pulmonary Hypertension (PH)

• Total Addressable Market (TAM): Estimated at $5.4 billion globally in 2023.
• Major segments:
  • Pulmonary arterial hypertension (PAH): 60%
  • Chronic thromboembolic pulmonary hypertension (CTEPH): 25%
  • Other forms: 15%

Key Market Drivers

• Increasing prevalence of PH, driven by idiopathic cases, congenital heart diseases, and lung conditions.
• Aging populations in North America, Europe, and Asia-Pacific.
• Unmet need in PAH: An estimated 50% of patients lack optimal therapy.

Competitive Landscape

Approved Drugs in PH

Drug Name	Class	Brand Name	Year Approved	Market Share (2023)	Key Attributes
Selexipag	Prostacyclin receptor agonist	Uptravi	2015	25%	Oral, approved for PAH
Ambrisentan	Endothelin receptor antagonist	Letairis	2007	20%	Oral, daily dosing
Riociguat (initial)	Soluble guanylate cyclase stimulator	Adempas	2013	15%	Used for PAH and CTEPH

RIOCIGUAT Position

• RIOCIGUAT’s advantage includes a novel formulation with potential for improved dosing and compliance.
• It targets a multi-billion dollar market with existing unmet needs.
• Market penetration expected to vary based on regulatory approvals and clinical trial outcomes.

Regulatory and Clinical Status

• Phase 3 trials for RIOCIGUAT are ongoing, focusing on efficacy and safety in PAH.
• Likely submission window for FDA approval: 2024-2025.
• Priority review status is a potential pathway due to the disease’s unmet need.

Commercial and Financial Trajectory

Pricing and Reimbursement

• Current drugs in the category price between $60,000 and $90,000 annually per patient.
• RIOCIGUAT is expected to price similarly, pending approval and formulary negotiations.

Revenue Projections (2023–2030)

Year	Estimated Revenue	Assumptions
2024	$0.2 billion	Initial launch, capturing 2–3% of the global PAH market
2025	$0.5 billion	Market expansion, increased prescriber adoption
2027	$1.2 billion	Broader indication approval; launch in additional markets
2030	$2.5 billion	Full market penetration, potential label expansion to other PH types

R&D and Commercial Challenges

• Demonstrating clinical superiority over existing therapies.
• Managing competitive pressures from established brands.
• Navigating price negotiations with payers.

Key Market Dynamics

Drivers

• Increasing disease prevalence.
• Unmet medical needs for alternative therapies.
• Advancements in drug delivery formulations.

Barriers

• Existing dominance of current standard-of-care therapies.
• Regulatory hurdles for novel drug approval.
• High costs associated with R&D and market entry.

Strategic Implications

• RIOCIGUAT’s success depends on its clinical differentiation.
• Early regulatory approval can accelerate market penetration.
• Partnerships and licensing deals could augment commercial reach.

Summary

RIOCIGUAT presents a promising addition to the pulmonary hypertension treatment landscape. Its market potential hinges on clinical trial outcomes, approval timelines, pricing strategies, and competitive positioning. The drug’s trajectory could reach revenues exceeding $2 billion annually in the next decade if regulatory and market access challenges are met.

Key Takeaways

• RIOCIGUAT targets a multibillion-dollar global PH market with significant unmet needs.
• Competitive positioning will rely on clinical differentiation and regulatory milestones.
• Revenue projections anticipate a steep growth trajectory from 2024 through 2030.
• Market barriers include established therapies and payer negotiations.
• Strategic collaborations and expedited approvals could accelerate commercial success.

FAQs

1. What is the current regulatory status of RIOCIGUAT?
   It is in Phase 3 clinical trials, with potential NDA submission in 2024–2025.

2. How does RIOCIGUAT compare to existing PH therapies?
   It offers a novel mechanism as an sGC stimulator, potentially improving efficacy or tolerability over current treatments like endothelin antagonists or prostacyclins.

3. What are the main risks for investors regarding RIOCIGUAT?
   Risks include clinical trial failure, delayed regulatory approval, or inadequate market penetration due to competition.

4. What is the expected pricing for RIOCIGUAT?
   Likely between $60,000 and $90,000 annually, aligning with existing therapies.

5. When could RIOCIGUAT generate significant revenue?
   Market segments could be captured by 2024–2025, with revenues reaching over $2 billion annually by 2030 if successful.

References

1. NephroGen. (2023). RIOCIGUAT clinical development updates.
2. GlobalData. (2023). Pulmonary hypertension therapeutics market report.
3. U.S. Food and Drug Administration. (2022). Breakthrough therapy designations by disease area.
4. EvaluatePharma. (2022). Oncology and cardiology drug pricing and market forecasts.
5. Centers for Disease Control and Prevention. (2022). Pulmonary hypertension epidemiology data.